IN2014DE00818A - - Google Patents

Download PDF

Info

Publication number
IN2014DE00818A
IN2014DE00818A IN818DE2014A IN2014DE00818A IN 2014DE00818 A IN2014DE00818 A IN 2014DE00818A IN 818DE2014 A IN818DE2014 A IN 818DE2014A IN 2014DE00818 A IN2014DE00818 A IN 2014DE00818A
Authority
IN
India
Prior art keywords
subject
diabetes
borapetoside
metabolite
prodrug
Prior art date
Application number
Inventor
Ming-Jai Su
Shoei-Sheng Lee
Original Assignee
Orient Europharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Orient Europharma Co Ltd filed Critical Orient Europharma Co Ltd
Priority to IN818DE2014 priority Critical patent/IN2014DE00818A/en
Publication of IN2014DE00818A publication Critical patent/IN2014DE00818A/en

Links

Landscapes

  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

The present invention is directed to therapeutic methods and compositions for treating insulin resistant diabetes or diabetes with inflammation in a subject comprising administering an effective amount of borapetoside A, or a pharmaceutically acceptable salt, metabolite, solvate or prodrug thereof, to said subject.
IN818DE2014 2014-03-20 2014-03-20 IN2014DE00818A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
IN818DE2014 IN2014DE00818A (en) 2014-03-20 2014-03-20

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IN818DE2014 IN2014DE00818A (en) 2014-03-20 2014-03-20

Publications (1)

Publication Number Publication Date
IN2014DE00818A true IN2014DE00818A (en) 2015-09-25

Family

ID=54394329

Family Applications (1)

Application Number Title Priority Date Filing Date
IN818DE2014 IN2014DE00818A (en) 2014-03-20 2014-03-20

Country Status (1)

Country Link
IN (1) IN2014DE00818A (en)

Similar Documents

Publication Publication Date Title
MX2023000320A (en) Methods of modulating drug plasma levels using erythrohydroxybupropion.
PH12016500582A1 (en) Heterocyclic compounds and uses thereof
MX2017004471A (en) Triazolopyridine compounds and methods for the treatment of cystic fibrosis.
MX2018006674A (en) Cancer treatment using 2-deoxy-2-fluoro-l-fucose in combination with a checkpoint inhibitor.
MX2016012021A (en) Heterocyclic compounds for use in the treatment of pi3k-gamma mediated disorders.
EP3141603A4 (en) Gpc3-targeted therapeutic agent for administration to patients for whom gpc3-targeted therapeutic agent therapy is effective
PH12017500933A1 (en) Sublingual administration of riluzole
PH12016502352A1 (en) Pharmaceutical composition
TW201613578A (en) Pharmaceutical combinations
PH12017500934A1 (en) Sublingual formulation of riluzole
WO2014160281A3 (en) Method of enhancing delivery of therapeutic compounds to the eye
MX2016016388A (en) Method of treating non-small cell lung cancer and/or small cell lung cancer using thienotriazolodiazepine compounds.
PH12016502233A1 (en) (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine
PH12016502236A1 (en) (r)-pirlindole and its pharmaceutically acceptable salts for use in medicine
MX2021014120A (en) Treatment of androgen deprivation therapy associated symptoms.
MX2016011706A (en) Progesterone formulations.
MX2018006631A (en) Compound for use in the prevention and treatment of neurodegenerative diseases.
MX2017014301A (en) Compositions and methods for the treatment or prevention of pulmonary hypertension.
IN2014DE00818A (en)
PH12014000105A1 (en) Therapeutic methods and compositions for treating diabetes utilizing diterpenoid compounds
IN2014DE00822A (en)
MX2016013979A (en) New administration routes of insulin, insulin analogs or derivatives of insulin.
MX2016010919A (en) 4-benzylsulfonyl-2-butenenitrile.
PL2852400T3 (en) An insulin analogue or its pharmaceutically acceptable salt, pharmaceutical composition with prolonged therapeutic effect, use of the insulin analogue, dosage method and method of treatment of diabetes